Researchers from the Department of Epidemiology and Biostatistics at MakSPH have contributed to a landmark global study proving that twice-yearly injections of Lenacapavir prevent HIV infection with 100% efficacy. Conducted under the PURPOSE 1 trial by Gilead Sciences, Uganda’s participation, led by MakSPH in collaboration with MU-JHU, AMBSO, UVRI, and IAVI, was critical to this breakthrough.

Building on earlier work by Prof. Noah Kiwanuka identifying high HIV risk among young women, the study represents a major leap in prevention science. Dr. Flavia Matovu Kiweewa, Uganda’s Principal Investigator, called the results “a milestone in HIV prevention.” Lenacapavir is expected to roll out in Uganda in 2026, offering new hope to vulnerable populations and reaffirming MakSPH’s leadership in transformative public health research.